Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus

NCT00030862 | Completed Phase 2

• 4 other identifiers: 01-123CDR0000069204PHARMACIA-440E-ONC-0020-319NCI-G01-2050
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining irinotecan and cisplatin in treating patients who have locally advanced unresectable or metastatic cancer of the esophagus that has not been previously treated.

Conditions

Esophageal Cancer

Keywords

stage II esophageal cancer; stage III esophageal cancer; stage IV esophageal cancer; squamous cell carcinoma of the esophagus; adenocarcinoma of the esophagus

Interventions

cisplatin DRUG

irinotecan hydrochloride DRUG

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

DISEASE CHARACTERISTICS: * Histologically confirmed squamous cell carcinoma or adenocarcinoma of the esophagus * Previously untreated * Locally advanced unresectable or metastatic disease * More than 50% of tumor must involve esophagus or gastroesophageal (GE) junction if tumor extends below the GE junction into the proximal stomach * At least 1 unidimensionally measurable lesion * At least 20 mm by conventional techniques OR * At least 10 mm by spiral CT scan * The following are not considered measurable disease: * Bone lesions * Leptomeningeal disease * Ascites * Pleural/pericardial effusions * Lymphangitis cutis/pulmonis * Abdominal masses not confirmed and followed by imaging techniques * Cystic lesions * Tumor lesions in previously irradiated areas * No carcinomatous meningitis or untreated brain metastases * Brain metastases allowed if asymptomatic and patient is on stable or tapering dose of steroids * Large pleural effusions must have been previously drained and sclerosed or otherwise controlled * Small, stable, asymptomatic pleural effusions allowed * Dysphagia allowed PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * ECOG 0-2 OR * Karnofsky 60-100% Life expectancy: * At least 3 months Hematopoietic: * Absolute neutrophil count at least 1,500/mm\^3 * WBC at least 3,000/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic: * Bilirubin no greater than 1.5 mg/dL * AST no greater than 3 times upper limit of normal (ULN) (5 times ULN if liver metastases present) * No known Gilbert's disease Renal: * Creatinine no greater than 1.5 mg/dL * Calcium less than 12.0 mg/dL Cardiovascular: * No history of significant cardiovascular disease * No inadequately controlled hypertension * No unstable angina * No myocardial infarction within the past 6 months * No ventricular cardiac arrhythmias requiring medication * No history or treatment for congestive heart failure Pulmonary: * No interstitial pneumonia * No fibroid lung Other: * No serious active infection * No uncontrolled diabetes mellitus (random blood sugar at least 300 mg) * No peripheral neuropathy grade 2 or greater * No other malignancy within the past 3 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or any other malignancy that does not carry a worse prognosis than advanced esophageal cancer * No other serious underlying medical condition that would preclude study * No other concurrent disease that would preclude study * No psychiatric illness or other significant mental impairment that would preclude study * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * No prior chemotherapy Endocrine therapy: * See Disease Characteristics Radiotherapy: * See Disease Characteristics * At least 2 weeks since prior radiotherapy and recovered * No prior radiotherapy to the pelvis Surgery: * See Disease Characteristics * Not specified Other: * No concurrent phenytoin or phenobarbital

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Memorial Sloan Kettering Cancer Center: lead
• National Cancer Institute (NCI): collaborator

Study Sites (1)

Memorial Sloan-Kettering Cancer Center

New York, New York, 10021, United States

Location

MeSH Terms

Conditions

Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Adenocarcinoma Of Esophagus

Interventions

Cisplatin; Irinotecan

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Head and Neck Neoplasms; Digestive System Diseases; Esophageal Diseases; Gastrointestinal Diseases; Carcinoma, Squamous Cell; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms, Squamous Cell

Intervention Hierarchy (Ancestors)

Chlorine Compounds; Inorganic Chemicals; Nitrogen Compounds; Platinum Compounds; Camptothecin; Alkaloids; Heterocyclic Compounds

Study Officials

• David H. Ilson, MD, PhD

  Memorial Sloan Kettering Cancer Center

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 2
• Purpose: TREATMENT
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: February 14, 2002
• First Posted: January 27, 2003
• Study Start: October 1, 2001
• Primary Completion: December 1, 2003
• Study Completion: December 1, 2003
• Last Updated: June 5, 2013

Record last verified: 2013-06

Locations

US (1)